134 related articles for article (PubMed ID: 32863193)
61. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.
Lee JH; Joo YD; Kim H; Bae SH; Kim MK; Zang DY; Lee JL; Lee GW; Lee JH; Park JH; Kim DY; Lee WS; Ryoo HM; Hyun MS; Kim HJ; Min YJ; Jang YE; Lee KH;
Blood; 2011 Oct; 118(14):3832-41. PubMed ID: 21828126
[TBL] [Abstract][Full Text] [Related]
62. A comparison of in vitro sensitivity of acute myeloid leukemia precursors to mitoxantrone, 4'deoxydoxorubicin, 4-demethoxydaunorubicin and daunorubicin.
Schölzel C; van Putten W; Löwenberg B
Leuk Res; 1986; 10(12):1455-9. PubMed ID: 3467144
[TBL] [Abstract][Full Text] [Related]
63. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
[TBL] [Abstract][Full Text] [Related]
64. [The role of daunorubicin in induction therapy for adult acute myeloid leukemia].
Usui N; Dobashi N; Asai O; Yano S; Kato A; Osawa H; Uno S; Katori M; Nagamine M; Yahagi Y; Yamaguchi Y; Saito T; Kasama K; Takei Y; Ogihara A; Yamazaki H; Kobayashi T; Tajima N; Ogawa M; Kuraishi Y
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1152-9. PubMed ID: 10945010
[TBL] [Abstract][Full Text] [Related]
65. Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study.
Reagan JL; Sullivan MR; Winer ES; Lansigan F; Cardin MS; Castillo JJ
Leuk Res; 2015 Aug; 39(8):812-7. PubMed ID: 26045177
[TBL] [Abstract][Full Text] [Related]
66. Role of daunorubicin in the induction therapy for adult acute myeloid leukemia.
Usui N; Dobashi N; Kobayashi T; Yano S; Maki N; Asai O; Saito T; Yamaguchi Y; Watanabe H; Kato A; Ogihara A; Katori M; Nagamine M; Takei Y; Yamazaki H; Funakoshi S; Tajima N; Ogawa M; Kuraishi Y
J Clin Oncol; 1998 Jun; 16(6):2086-92. PubMed ID: 9626208
[TBL] [Abstract][Full Text] [Related]
67. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
[TBL] [Abstract][Full Text] [Related]
68. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
69. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
70. [Efficacy of Different Doses of Daunorubicin Induced Chemotherapy in Patients with Newly Diagnosed Primary Acute Myeloid Leukemia Under 65 Years Old].
Gong SG; Wang FJ; Wang ST; Zheng Q; Shuai X; Ma HB; Zhang L; Chen XC; Wu Y; Jia YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1071-1079. PubMed ID: 34362484
[TBL] [Abstract][Full Text] [Related]
71. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Attar EC; Johnson JL; Amrein PC; Lozanski G; Wadleigh M; DeAngelo DJ; Kolitz JE; Powell BL; Voorhees P; Wang ES; Blum W; Stone RM; Marcucci G; Bloomfield CD; Moser B; Larson RA
J Clin Oncol; 2013 Mar; 31(7):923-9. PubMed ID: 23129738
[TBL] [Abstract][Full Text] [Related]
72. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A; Robak T; Lech-Marańda E; Wierzbowska A; Dmoszyńska A; Kowal M; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Maj S; Hellmann A; Skotnicki A; Jedrzejczak W; Kuliczkowski K;
Eur J Haematol; 2003 Sep; 71(3):155-62. PubMed ID: 12930315
[TBL] [Abstract][Full Text] [Related]
73. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
Kolitz JE; George SL; Benson DM; Maharry K; Marcucci G; Vij R; Powell BL; Allen SL; Deangelo DJ; Shea TC; Stock W; Bakan CE; Hars V; Hoke E; Bloomfield CD; Caligiuri MA; Larson RA;
Cancer; 2014 Apr; 120(7):1010-7. PubMed ID: 24382782
[TBL] [Abstract][Full Text] [Related]
74. Chemotherapy options for previously untreated acute myeloid leukemia.
Lynch RC; Medeiros BC
Expert Opin Pharmacother; 2015; 16(14):2149-62. PubMed ID: 26364895
[TBL] [Abstract][Full Text] [Related]
75. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
[TBL] [Abstract][Full Text] [Related]
76. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
[TBL] [Abstract][Full Text] [Related]
77. Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen.
Beguin Y; Sautois B; Forget P; Bury J; Fillet G
Cancer; 1997 Apr; 79(7):1351-4. PubMed ID: 9083157
[TBL] [Abstract][Full Text] [Related]
78. A new combination of two intercalating agents (mitoxantrone + daunomycin) in adult refractory acute leukemia: the DON protocol.
Laporte JP; Gorin NC; Lemonnier MP; Isnard F; Najman A
Cancer Chemother Pharmacol; 1988; 22(4):344-7. PubMed ID: 3168147
[TBL] [Abstract][Full Text] [Related]
79. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.
Estey E; Thall PF; Kantarjian H; O'Brien S; Koller CA; Beran M; Gutterman J; Deisseroth A; Keating M
Blood; 1992 May; 79(9):2246-55. PubMed ID: 1571541
[TBL] [Abstract][Full Text] [Related]
80. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
Paciucci PA; Cuttner J; Holland JF
Semin Oncol; 1984 Sep; 11(3 Suppl 1):36-40. PubMed ID: 6385264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]